What Ani Biome does

Ani Biome operates a San Francisco-based research lab branded as ANI.AI, developing what it describes as the computational substrate for longevity medicine. Its core product is the ANI Platform, which integrates deep multiomics, longitudinal digital phenotyping, validated functional and cognitive assessments, monitored intervention exposure, and structured physician decisions into a unified learned latent representation of human biological state. Two proprietary analytical constructs anchor the platform: the Coherence Framework, which quantifies inter-system coordination through cross-system covariance, temporal alignment, and propagation depth across longitudinal multiomics; and the Identity Mask, a privacy-preserving geometric representation of an individual's biological state derived from the ANI latent space. The lab also operates AgeBiotics, an intervention layer comprising AB-01 (a liquid small-molecule matrix from controlled fermentation) and AB-02 (a capsule cofactor formulation), studied as defined inputs into the platform's response loop.

The company's go-to-market is community-led and research-collaboration-based rather than commercially transacted. An application-based Research Credits Program distributes platform credits, response-state modeling support, digital phenotyping infrastructure, and up to USD 5,000 per approved participant in credited multiomics services to research groups, clinicians, and translational teams studying aging, cognition, muscle, immunity, metabolism, microbiome, rehabilitation, and adaptive intervention. The flagship human substrate is the ELITE healthspan intervention trial at Sheba Medical Center, conducted with the Sheba Longevity Center under Principal Investigator Dr Evelyne Bischof. In May 2025 the company was selected for both the XPRIZE Healthspan competition and the FSHD Bonus Prize, the only entrant chosen for both tracks.

Ani Biome is structured as ANI Biome PBC, a Public Benefit Corporation incorporated in California. Co-founders Bruno Balen and Nika Pintar serve as co-CEOs covering AI orchestration/response-state modeling and clinical deployment/regulatory/bioinformatics respectively. Prof Michael Snyder (Chair of Genetics, Stanford University) sits on the board. The company does not disclose funding rounds, revenue, cap-table data, or paid customers in the available source material, and pricing for the platform is explicitly not publicly disclosed.

Name

Ani Biome

Legal name

ANI Biome PBC

Website

https://anibiome.ai

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Ani Biome is a San Francisco-based longevity biotech research lab building the ANI Platform, which integrates deep multiomics, longitudinal digital phenotyping, and physician decisions into a learned latent model of human biological state for clinical research groups, translational teams, and longevity clinicians via an application-based research credits program.

Ownership category

akta.pro rank

Product category

Longevity Research Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Longevity research platform
• Multiomics data integration
• Digital phenotyping infrastructure
• Healthspan intervention trials
• Biological coherence modeling

Headquarters

HQ city

Ljubljana

HQ country

Slovenia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

AnI Biome builds the ANI research platform that integrates deep multiomics, longitudinal digital phenotyping, and physician-supervised intervention into a unified latent representation of human biological state for individualized response measurement. The company runs the ELITE healthspan intervention trial at Sheba Medical Center and offers the AgeBiotics intervention layer (AB-01 liquid matrix and AB-02 capsule cofactors). Access is provided via a Research Credits Program where selected collaborators receive platform credits, response-state modeling support, and up to USD 5,000 per approved participant in multiomics services.

Product overview

ANI Biome is a San Francisco research lab developing ANI, a research platform for autonomous intelligence for human biology. The portfolio consists of the ANI Platform (the core computational substrate integrating multiomics, digital phenotyping, and clinical data into a unified state model), the ELITE Trial (healthspan intervention study at Sheba Medical Center), AgeBiotics interventions (AB-01 and AB-02 formulations), the Identity Mask (privacy-preserving geometric representation of biological state), the Coherence Framework (inter-system coordination quantification), and a Research Credits Program for cohort collaborations. The platform enables individualized response measurement through learned latent representations rather than population averages.

Differentiator

Problem solved

Functional benefit

Brands

• ELITE: Healthspan intervention trial at Sheba Medical Center conducted with the Sheba Longevity Center under principal investigator Dr Evelyne Bischof, pairing physician-supervised intervention with deep longitudinal phenotyping.
• AgeBiotics
• ANI Platform

Products and services

• ANI Platform Research platform integrating deep multiomics, longitudinal digital phenotyping, and physician-supervised intervention into a unified latent representation of human biological state for individualized response measurement, clinical decision support, and AI-agent reasoning. Targeted at research groups, clinicians, and translational teams studying aging and related domains.
• ELITE Trial Healthspan intervention trial at Sheba Medical Center conducted with the Sheba Longevity Center under PI Dr Evelyne Bischof, pairing physician-supervised intervention with deep longitudinal phenotyping including scheduled bloodwork, multiomics, microbiome sampling, validated functional and cognitive endpoints, and digital monitoring.
• AgeBiotics (AB-01 and AB-02) Intervention layer comprising AB-01 (liquid small-molecule matrix produced through controlled fermentation chemistry) and AB-02 (capsule cofactor formulation), studied as defined inputs into the ANI response loop with effects characterized across microbiome ecology, metabolic flux, mitochondrial function, redox handling, and inflammatory signaling.
• Research Credits Program Collaboration program offering ANI platform credits, response-state modeling support, digital phenotyping infrastructure, and up to USD 5,000 per approved participant in credited multiomics services for research groups, clinicians, and translational teams studying aging, cognition, muscle, immunity, metabolism, microbiome, rehabilitation, and adaptive intervention.

Quantifiable outcome

• XPRIZE Healthspan target: restoration of 20 years of muscular, cognitive, and immune function
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Sheba Medical Center / Sheba Longevity CentercoreStrategic or Co-development Partner · 1 May 2025ELITE is the healthspan intervention trial conducted at Sheba Medical Center under the Sheba Longevity Center. The protocol pairs physician-supervised intervention with deep longitudinal phenotyping including scheduled bloodwork, multiomics, microbiome sampling, validated functional and cognitive endpoints, and digital monitoring across the trial arc. Dr Evelyne Bischof serves as Principal Investigator and Medical Director of Sheba Longevity Center.
• Stanford UniversitycoreStrategic or Co-development PartnerProf Michael Snyder, Chair of Genetics at Stanford University, serves on the Board of ANI Biome. He provides scientific oversight and expertise in longitudinal multiomics, which is central to the company's approach.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Insilico Medicine: AI-driven drug discovery and longevity company using deep learning and multiomics to identify aging biology and therapeutic targets; comparable as a longevity-AI platform with proprietary computational biology IP and clinical-stage interventions.
• Recursion Pharmaceuticals: AI-driven biology platform combining high-dimensional phenotypic data and machine learning to map biology and discover drugs; overlaps with ANI as a multiomics/integrated computational biology company targeting complex phenotypes including aging.
• BioAge Labs: Clinical-stage biopharmaceutical company using omics data and AI to identify drivers of human aging and develop therapeutics; directly comparable as a longevity biotech built on multiomics-driven intervention development.
• NewLimit: AI-focused longevity company developing epigenetic reprogramming therapies to extend human healthspan; comparable as a private longevity-AI platform with intervention development and long-horizon science ambitions.
• Altos Labs: Well-funded longevity biotech focused on cellular rejuvenation programming to restore cell health and reverse disease; comparable as a serious longevity platform player pursuing biological-age reversal via deep biology and clinical translation.
• Tempus Labs: AI-enabled precision medicine company integrating multiomics (genomics, transcriptomics, proteomics) with clinical data to enable physicians and researchers; overlaps with ANI on the multiomics-platform-for-clinicians positioning.
• Human Longevity Inc. Precision-medicine and longevity company combining whole-genome sequencing, multiomics, and AI to deliver comprehensive health assessments; overlaps as a multiomics/AI-driven platform aimed at healthspan and longevity medicine.

Emerging players

• Owkin: AI-biotech applying federated learning and multimodal biological data (multiomics, imaging, clinical) to research and clinical workflows; overlaps conceptually on multiomics/AI platform for precision medicine though focused on oncology and translational research.
• Deep Genomics: AI platform for RNA biology and oligonucleotide drug discovery using deep learning on biological data; comparable as an AI-native computational biology platform that integrates molecular data with biological modeling.

Broad incumbents

• Calico Life Sciences: Alphabet-backed longevity R&D company pursuing fundamental biology of aging and developing interventions; comparable as a large, established longevity platform operating with deep capital and longer time horizons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/anibiome
• LinkedInlinkedin.com/company/anibiome

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ani Biome